Physiology‐based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab
Abstract Type I interferons contribute to the pathogenesis of several autoimmune disorders, including systemic lupus erythematosus (SLE), systemic sclerosis, cutaneous lupus erythematosus, and myositis. Anifrolumab is a monoclonal antibody that binds to subunit 1 of the type I interferon receptor (I...
Збережено в:
| Автори: | , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Wiley
2025-01-01
|
| Серія: | CPT: Pharmacometrics & Systems Pharmacology |
| Онлайн доступ: | https://doi.org/10.1002/psp4.13245 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|